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he Clinical Results of a Platelet
lycoprotein IIb/IIIa Receptor Blocker (Abciximab:
eoPro)-Coated Stent in Acute Myocardial Infarction
eon Kim, MD,* Myung Ho Jeong, MD, FACC, FAHA, FESC,* Kye Hun Kim, MD,*
l Suk Sohn, MD,* Young Joon Hong, MD,* Hyung Wook Park, MD,* Ju Han Kim, MD,*
oung Keun Ahn, MD, FACC,* Jeong Gwan Cho, MD, FACC,* Jong Chun Park, MD,*
ong Lyun Cho, PHD,† Jung Chae Kang, MD*
wangju, Korea
OBJECTIVES This study is a prospective randomized trial investigating clinical outcomes of patients with
acute myocardial infarction (AMI) treated with abciximab (ReoPro)-coated stents.
BACKGROUND Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the
prevention of coronary restenosis.
METHODS Ninety-six patients with AMI were randomly allocated into two groups; group I received
abciximab-coated stents (n 48, 57.1 12.0 years), and group II received bare metal control
stents (n  48, 58.4  11.6 years).
RESULTS At baseline, clinical characteristics, percent diameter stenosis, and minimal luminal diameter
were no different between the two groups. One patient in group II had reinfarction and target
lesion reintervention during hospital stay. Follow-up coronary angiography was obtained in
77.1% (37 of 48) in group I and 75.0% (36 of 48) in group II. Percent diameter stenosis and late
loss were significantly lower in group I than group II (18.9 5.54% vs. 37.9 6.25%, p 0.008;
and 0.39 0.29 mm vs. 0.88 0.45 mm; p 0.008, respectively). At follow-up intravascular
ultrasound, intrastent lumen area and intrastent neointimal hyperplasia (NIH) area were 5.4
 1.8 mm2 and 2.2  1.5 mm2, respectively, in group I and 4.3  1.6 mm2 and 3.4  1.8
mm2, respectively, in group II (p  0.045). And, in-stent restenosis rate was lower in group
I than group II (p  0.011 and p  0.008, respectively). During 1-year follow-up, two
patients in group II (4.1%) had AMI, whereas no patient in group I suffered AMI. Target
lesion revascularization and total major adverse cardiac events rates were relatively lower in
group I compared with those in group II (10.4% [5 of 48] vs. 20.8% [10 of 48], p  0.261,
and 10.4% vs. 25.0%, p  0.107, respectively).
CONCLUSIONS Abciximab-coated stent implantation was safe and effective without stent thrombosis in AMI
patients. (J Am Coll Cardiol 2006;47:933–8) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.054Cardiology Foundation
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She development of coronary artery stenting reduces the
ncidence of acute coronary occlusion after percutaneous trans-
uminal coronary angioplasty to 1% (1). In-stent restenosis
aused by intimal hyperplasia, however, still occurs in as
igh as 10% of patients even after drug-eluting stent (DES)
nd thereby remains a significant clinical problem to be
olved (2). It has been shown that stents coated with
ntiproliferative agents such as sirolimus and paclitaxel are
ssociated with lower restenosis rates, after percutaneous
oronary intervention (PCI), than conventional bare-metal
tents. More recent reports have also shown the efficacy of
hese DES under more challenging conditions, such as
From the *Heart Center of Chonnam National University Hospital, Chonnam
ational University Research Institute of Medical Sciences, and †Chemical Engi-
eering of Chonnam National University, Gwangju, Korea. This study was supported
y grants from the Cardiovascular Research Foundation Asia, the Health Technology
esearch and Development Program of the Ministry of Health and Welfare
01-PJ1-PG3-20500-0016), and from the Clinical Research Institute of Chonnam
ational University Hospital (CUHRI-U-200125).w
Manuscript received August 31, 2005; revised manuscript received October 10,
005, accepted October 18, 2005.mall vessels, lesions of in-stent restenosis, diabetics, and
ong and complex lesions (3–7).
Abciximab, a potent antiplatelet agent that blocks the
nal pathways to platelet aggregation, improves outcomes of
igh-risk PCI and decreases the incidence of major adverse
ardiac events (MACE) (8–11). Differently from other
inds of platelet glycoprotein IIb/IIIa receptor blockers, it
lso binds to Mac-1 (CD11b/18) on vascular endothelial cells
nd macrophages, thereby inhibiting inflammatory responses
nd smooth muscle cell proliferation after vascular injury
12–17). Recently, we demonstrated that abciximab-coated
tents were safe and effective in the prevention of coronary
estenosis in humans as well as in a porcine model (18,19).
The aim of the present study is to evaluate clinical and
ngiographic outcomes of abciximab-coated stent implan-
ation in patients with acute myocardial infarction (AMI).
ETHODS
tudy group. Ninety-six patients with AMI who under-
ent PCI at Chonnam National University Hospital
w
g
(
b
p
d
a
l
s
d
s
s
a
s
p
M
A
c
i
t
t
t
g
a
f
I
t
c
t
s
m
s
S
I
t
1
c
d
p
p
m
7
5
U
t
a
T
3
r
o
g
p
n
s
o
a
fl
i
M
o
o
c
d
d
t
d
P
s
i
w
d
n
(
a
a
m
E
C
S
6
a
l
l
e
a
l
S
p
d
t
e
t
o
a
u
e
a
p
934 Kim et al. JACC Vol. 47, No. 5, 2006
Abciximab-Coated Stent in AMI March 7, 2006:933–8ere recruited and then randomly divided into two
roups: group I, which received abciximab-coated stents
n  48), and group II, which received conventional
are-metal stents (n 48). The inclusion criteria were AMI
atients with age range from 18 to 80 years, target vessel
iameter between 2.5 and 4.0 mm, lesion length 25 mm,
nd critical stenosis (70%) on angiography. Patients with
eft main-stem stenosis, graft-vessel stenosis, cardiogenic
hock, left ventricular ejection fraction 35%, or contrain-
ications for antiplatelet agents were excluded from the
tudy. The study protocol was reviewed and approved in
equence by the Korean Ministry of Health and Welfare
nd the Ethics Committee of Chonnam National Univer-
ity Hospital, and informed consent was obtained from all
atients.
anufacturing process of the abciximab-coated stent.
bciximab-coated stents were used according to the proto-
ol previously described (18,19). Briefly, a plasma polymer-
zation reaction was performed to attach amine radicals to
he stent surface. For the attachment of amine radicals to
he stent surface, diaminocyclohexane monomer was drifted
o the tubular reactor in a constant dose, and plasma was
enerated with a radiofrequency power generator. The
bciximab used was a human-murine chimeric antibody Fab
ragment, ReoPro (Eli Lilly and Company, Indianapolis,
ndiana). The carboxy radical of abciximab was introduced
o the amine radicals attached to the stent to achieve
ovalent bonding and improved attachment power between
he stent and abciximab. The abciximab coating on the
urface of the stent was confirmed by scanning electron
icroscopy. For the release, kinetics of abciximab from the
tent was done.
tudy procedure, stent implantation, angiography, and
VUS. All other procedures were performed by standard
echniques: randomly selected stents were deployed at 10 to
6 atmospheric pressure after predilation with a balloon
atheter. In cases with residual stenosis, additional balloon
ilatation was performed after stenting. None of the study
atients received glycoprotein IIb/IIIa receptor blockers. All
atients received aspirin (300 mg loading and 100 to 200
g/day indefinitely) and clopidogrel (300 mg loading and
5 mg/day for 2 months). Heparin was administered as
,000-U bolus, followed by 1,000 U/h and additional 5,000
immediately before PCI to keep the activated clotting
ime (ACT) at 250 to 300 s. Successful PCI was defined as
patent vessel at the treatment site with anterograde
Abbreviations and Acronyms
AMI  acute myocardial infarction
DES  drug-eluting stent
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarctionhrombolysis In Myocardial Infarction (TIMI) flow grade (and angiographic residual stenosis 20% without occur-
ence of any cardiac events.
Acute myocardial infarction was defined as the presence
f typical chest pain, ischemic change on the electrocardio-
ram in two or more contiguous leads, and peak elevation of
lasma creatine kinase (CK) and CK-MB to at least twice
ormal. Stent thrombosis was defined as an acute coronary
yndrome with angiographic documentation of either vessel
cclusion (TIMI flow grade 0 or 1) or thrombus within or
djacent to a previously successfully stented vessel (TIMI
ow grade 1 or 2).
Bleeding events were classified as major, minor, or insignif-
cant according to the criteria of the TIMI Study Group.
ajor bleeding events were defined as intracranial bleeding
r a bleeding event that caused fall in hemoglobin of4 g/dl
r that required transfusion of 3 U of blood. Thrombo-
ytopenia was defined as a platelet count100 103/mm3.
Coronary angiography was performed at baseline, imme-
iately after the procedure, and 6 months later. Quantitative
iameter measurements of the coronary arteries were ob-
ained by a blinded reviewer using a workstation with
edicated software (Philips H5000 or Allura DCI program,
hilips Medical Systems, Eindhoven, the Netherlands) by a
tandard technique. In-stent restenosis was defined as an
n-stent luminal diameter stenosis 40%. Late lumen loss
as defined as the difference between the minimal luminal
iameter immediately after stenting and the minimal lumi-
al diameter at follow-up. The intravascular ultrasound
IVUS) imaging was performed in all patients before and
fter procedure and at follow-up. The IVUS images were
cquired with motorized pullback at a constant speed of 1
m/s (Galaxy, Boston Scientific, Natick, Massachusetts, or
ndosonics, EndoSonics Corporation, Rancho Cordova,
alifornia).
tudy end points. Clinical evaluation was done at 30 days,
months, and 1 year to assess patient symptom frequency
nd cardiac event rates. The primary end point was in-stent
ate lumen loss and the secondary end point was intrastent
uminal volume by IVUS and composite of major cardiac
vents, including cardiac death, any myocardial infarction,
nd percutaneous or surgical revascularization of the target
esion 12 months after procedure.
tatistical analysis. We calculated that with a sample of 96
atients, the study would have 80% power to detect a
ifference in the mean late luminal loss of 0.30 mm between
he two groups, assuming a standard deviation of 0.5 mm in
ach group, with the use of a two-group t test and a
wo-sided significance level of 0.5. All analyses were based
n the intention-to-treat principle. For continuous vari-
bles, differences between the treatment groups were eval-
ated by analysis of t test. For categorical variables, differ-
nces were expressed as counts and percentages and were
nalyzed with the chi-square test. Statistical analysis was
erformed with the aid of commercially available software
SPSS Version 10.0, SPSS Inc., Chicago, Illinois).
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aseline clinical characteristics. Clinical characteristics
or patients are shown in Table 1. No significant difference
as observed in the clinical characteristics between the two
roups. At presentation, ST-segment elevation myocardial
nfarction was diagnosed in 37 patients (77.1%) in group I
nd 35 (72.9%) in group II.
rocedural characteristics. Angiographic characteristics
or patients are shown in Table 2. There were no differences
etween the two groups in the location of culprit vessels,
esion type, or number of diseased vessels. In all cases stent
Table 1. Baseline Clinical Characteristics
Group
Abciximab
Age (yrs) 57.1
Men (%) 41
Risk factor (%)
Current smoking 27
Hypertension 24
Hypercholesterolemia 10
Diabetes mellitus 9
Clinical diagnosis (%)
Non–ST-segment elevation MI 11
ST-segment elevation MI 37
Combined vascular disease (%)
Peripheral 2
Non-hemorrhagic stroke 1
Hemorrhagic stroke 0
Family history 4
Previous coronary procedure (%) 1
Previous MI 1
Left ventricular function (%)
Mean ejection fraction 58.
MI  myocardial infarction.
able 2. Coronary Angiographic Characteristics
Group I Group II p
iseased vessels (%) 0.456
Right coronary artery 16 (33.3) 12 (25.0)
Left anterior descending artery 26 (54.2) 26 (54.2)
Left circumflex artery 6 (12.5) 10 (20.8)
iseased vessel number (%) 0.131
One-vessel 42 (87.5) 34 (70.8)
Two-vessel 5 (10.4) 12 (25.0)
Three-vessel 1 (2.1) 2 (4.2)
CC/AHA classification (%) 0.814
Type B1 37 (77.1) 35 (72.9)
Type B2 11 (22.9) 13 (27.1)
re-PCI TIMI flow (%) 0.223
TIMI flow grade 0 4 (8.3) 9 (18.8)
TIMI flow grade 1 2 (4.2) 1 (2.1)
TIMI flow grade 2 16 (33.3) 9 (18.8)
TIMI flow grade 3 26 (54.2) 29 (60.4)
re-dilation balloon (mm)
Balloon length 20.0  0.0 20.3  1.7 0.314
Balloon size 3.34  0.34 3.26  0.36 0.137
tent size (mm) 3.38  0.37 3.31  0.36 0.338
tent length (mm) 18.0  2.48 18.2  3.79 0.282CC/AHA American College of Cardiology/American Heart Association; PCI
ercutaneous coronary intervention; TIMI Thrombolysis In Myocardial Infarction.
Teployment was preceded by balloon predilation, and the
iameter of used catheters was no different between the
roups. Stent length was 18.0  2.48 mm in group I and
8.2  3.79 mm in group II. Stent diameter was 3.38 
.37 mm in group I and 3.31  0.36 mm in group II
Table 2). No significant bleeding or hemorrhagic events
ere observed in either group (Table 3).
uantitative coronary angiography. Six-month angio-
raphic follow-up was obtained in 37 patients (77.1%) in
roup I and in 36 (75.0%) in group II. In-stent restenosis
as found in 5 patients (13.9%) in group I and 12 (34.3%)
n group II (p 0.045). Percentage of diameter stenosis was
ignificantly lower in group I than group II (18.9 
.54% vs. 37.9  6.25%, p  0.002). Late loss was also
ignificantly lower in group I as compared with that in
roup II (0.39  0.29 mm vs. 0.88  0.45 mm, p 
.008) (Table 4).
VUS results. Serial IVUS measurements are shown in
able 5. Baseline stent and reference measurements were
imilar between the two groups. In the stented segment of
he two groups from after-stent implantation to follow-up,
 48) Group II (n  48)
pted Stent Control Stent
2.0 58.4  11.6 0.577
) 39 (81.3) 0.785
) 29 (60.4) 0.500
) 20 (41.7) 0.539
) 12 (25.0) 0.809
) 10 (20.8) 1.00
0.814
) 13 (27.1)
) 35 (72.9)
0 (0.0) 0.495
1 (2.1) 1.00
1 (2.1) 1.00
2 (4.2) 0.677
1 (2.1) 1.00
0 (0.0) 1.00
.9 57.6  11.1 0.654
able 3. Bleeding and Hematologic Complications
fter Stenting
Group I Group II p
ajor bleeding (%) 0 0 1.00
ntracranial hemorrhage (%) 0 0 1.00
inor bleeding (%)
Vascular access site
(hematoma 5 cm)
0 0 1.00
Vascular access site (5 cm) 1 (2.1) 1 (2.1) 0.131
Gingival bleeding 0 1 (2.1) 1.00
Gastrointestinal bleeding 0 0 1.00
Urinary tract bleeding 0 1 (2.1) 1.00
ny stroke (%) 0 0 1.00I (n
-Coa
 1
(85.4
(56.3
(50.0
(20.8
(18.8
(22.9
(77.1
(4.2)
(2.1)
(0.0)
(8.3)
(2.1)
(2.1)
8  8hrombocytopenia (100,000 mm3) 0 0 1.00
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Abciximab-Coated Stent in AMI March 7, 2006:933–8here was a decrease in lumen cross-sectional area and an
ncrease in neointimal hyperplasia area. A net decrease in
umen cross-sectional area was smaller in group I than in
roup II (2.2  1.5 mm2 vs. 3.4  1.8 mm2, p  0.008),
nd a net increase in neointimal hyperplasia area was smaller
n group I than in group II (2.2  1.5 mm2 vs. 3.4  1.8
m2, p  0.008).
n-hospital and follow-up results. During the hospital
tay, one patient in group II had AMI as a result of acute
hrombotic occlusion and underwent emergent revascular-
zation. Complete clinical follow-up was available for 97.9%
f the patients in both groups. One patient in group II had
ardiac death. Two patients in group II (4.2%) had AMI,
hereas no patient in group I suffered AMI. Target lesion
evascularization was necessary in 5 patients (10.4%) in
Table 5. Intravascular Ultrasound Results
Preintervention
Proximal reference EEM CSA (mm2)
Lesion site EEM CSA (mm2)
Lesion site lumen area (mm2)
Lesion site plaque plus media CSA (mm2)
Lesion site plaque burden (%)
Distal reference EEM CSA (mm2)
Postintervention stent CSA (mm2)
Follow-up
Proximal reference EEM CSA (mm2)
Lesion site EEM CSA (mm2)
Stent CSA (mm2)
Intrastent lumen area (mm2)
Intrastent neointimal hyperplasia area (mm2)
Distal reference EEM CSA (mm2)
Serial (after intervention to follow-up) comparison
Delta proximal reference EEM CSA (mm2)
Delta stent cross-sectional area (mm2)
Delta intrastent lumen area (mm2)
Delta intrastent neointimal hyperplasia area (mm2
Delta distal reference EEM CSA (mm2)
able 4. Quantitative Coronary Angiographic Results of
tented Segment
Group I Group II p
ollow-up CAG number (%) 37 (77.1) 36 (75.0) 1.00
estenosis rate (%) 5 (13.9) 12 (34.3) 0.045
efore stenting
RD (mm) 2.95  0.45 3.02  0.51 0.751
MLD (mm) 0.91  0.37 0.99  0.41 0.418
DS (%) 70.7  18.1 68.5  15.1 0.214
Lesion length (mm) 10.7  5.05 11.9  4.89 0.745
ost-stenting
RD (mm) 3.01  0.41 2.99  0.38 0.807
MLD (mm) 2.64  0.51 2.62  0.53 0.912
DS (%) 12.3  7.40 14.1  6.75 0.417
ollow-up
MLD (mm) 2.23  0.58 1.72  0.59 0.008
DS (%) 18.9  5.54 37.9  6.25 0.002
ate loss (mm) 0.39  0.29 0.88  0.45 0.008
AG  coronary angiogram; DS  diameter stenosis; MLD  minimal luminal
iameter; RD  reference diameter.CSA  cross-sectional area; EEM  external elastic membrane.roup I and 10 patients (20.8%) in group II; however, the
ncidence of overall MACE was relatively lower in group I
han group II (n  5 [10.4%] vs. n  12 [25.0%]; p 
.107) (Table 6).
ISCUSSION
he use of abciximab in patients with acute coronary
yndrome was associated with reductions in the magnitude
f rise in levels of circulating inflammatory markers after
CI. This anti-inflammatory effect of abciximab might be
ccounted for by the fact that it cross-reacts with Mac-1
CD11b/18), a leukocyte integrin that mediates firm adhe-
ion and transplatelet migration of leukocytes on vascular
hrombus, thereby inhibiting inflammatory reactions occur-
ing after vascular injury (15–17,20,21). Furthermore, ex-
ept for other small molecular weight glycoprotein IIb/IIIa
nhibitors, abciximab is known to bind to the vitronectin
eceptors found on platelets and vascular endothelial and
mooth muscle cells and exert an inhibitory effect on migration
nd proliferation of smooth muscle cells after acute vessel
njury (12–14). Coronary stenting in patients with AMI has
roblems to solve such as restenosis and reocclusion of
nfarct-related arteries.
This study is the first randomized, prospective clinical
rial evaluating effects of abciximab-coated stents in patients
ith AMI. Patients who received abciximab-coated stents
ere free of procedure-related complications, and the inci-
ence of in-hospital and 30-day MACE in this patient
opulation was not significantly different when compared
ith patients who received uncoated control stents. Because
ll cases recruited for this study had not received PCI within
h, it is difficult to interpret our results in the same context
s that of other primary PCI studies. In terms of restenosis
Group I Group II p
15.3  3.1 15.2  4.1 0.832
14.8  3.7 14.3  5.9 0.504
4.1  0.9 3.7  0.6 0.347
10.7  3.0 10.6  5.6 0.880
72.3  8.3 74.1  10.3 0.619
13.7  4.2 13.4  3.8 0.604
7.7  2.4 7.8  2.2 0.858
15.1  3.5 15.0  3.0 0.811
14.7  3.8 14.3  5.6 0.532
7.6  2.6 7.7  2.4 0.878
5.4  1.8 4.3  1.6 0.011
2.2  1.5 3.4  1.8 0.008
13.6  4.8 13.5  3.4 0.867
0.2  0.7 0.2  1.0 0.961
0.1  1.3 0.1  1.1 0.968
2.2  1.5 3.4  1.8 0.008
2.2  1.5 3.4  1.8 0.008
0.1  1.2 0.1  1.4 0.967)
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March 7, 2006:933–8 Abciximab-Coated Stent in AMInd target lesion revascularization rates, however, our results
13.9% and 10.4%, respectively) were superior to those of
he Stent PAMI (22) trial (20.3% and 7.7%) or the
ADILLAC (23) study (22.2% and 8.9%), which com-
ared outcomes of stenting in AMI patients. Moreover,
hese results are less favorable compared with those of
irolimus-eluting stent implantation by Saia et al. (24) (late
oss:0.04 0.25 mm) and Lemos et al. (25) (target lesion
evascularization rate: 1.1%; MACE rate: 9.4%). The inci-
ence of overall MACE was lower in the abciximab-coated
tent group, which was primarily attributed to a decrease in
he incidence of AMI. In fact, as was suggested by Jeremia
t al. (26), who reported that the incidence of stent
hrombosis after sirolimus-eluting stent implantation was
nly 1.1%, which is similar to that after conventional
tenting, acute or subacute stent thrombosis associated with
rug-eluting stent implantation is not thought to be clini-
ally significant.
Although the patient number was relatively small, the
bsence of episodes of AMI by acute or subacute thrombotic
cclusion during one-year clinical follow-up in the patients
ho received abciximab-coated stents suggests that platelet
ggregation was effectively inhibited with use of abciximab,
nd this effect could be maintained for a long-term period.
ostprocedural clopidogrel was given for two months ac-
ording to the same protocol for conventional stenting,
hereas it was prescribed for a more prolonged period of
ime in the trials using DES. Abciximab-coated stent implan-
ation was not associated with significant bleeding complica-
ions. No patient in either group received platelet glycoprotein
Ib/IIIa blockers during PCI, and there was no difference in
he postprocedural antiplatelet regimen between the two
roups.
One of the main limitations of this study is that PCI was
ot performed at least within 6 h of onset of chest pain in
ll cases, whereby the true effects of abciximab-coated stents
n AMI might have been rendered less pronounced. And
hen, this clinical study included only 98 patients with de
able 6. In-Hospital Primary Outcomes After Stenting
Group I
(n  48)
Group II
(n  48) p
uccess rate (%) 48 (100) 48 (100) 1.00
rimary end points (%)
Cardiac death 0 (0.0) 0 (0.0) 1.00
Acute myocardial infarction 0 (0.0) 1 (2.1) 1.00
Emergent revascularization 0 (0.0) 1 (2.1) 1.00
Emergent bypass surgery 0 (0.0) 0 (0.0) 1.00
linical follow-up number 47 (97.9) 47 (97.9)
otal follow-up MACE 5 (10.4) 12 (25.0) 0.107
Cardiac death 0 (0.0) 1 (2.1) 1.00
Acute myocardial infarction 0 (0.0) 2 (4.2) 0.495
TLR 5 (10.4) 10 (20.8) 0.261
Symptomatic angina 1 (2.1) 5 (10.4) 0.204
CABG 0 (0.0) 0 (0.0) 1.00
ABG  coronary artery bypass graft; MACE  major adverse cardiac events;
LR  target lesion revascularization.ovo, single vessel stenting, and follow-up coronary angio-
1ram was performed in only 75% to 77% patients. Further-
ore, it is only a single center study.
In conclusion, abciximab-coated stents in AMI patients
ere feasible and safe. Low rates of restenosis and revascu-
arization were observed. At one-year clinical follow-up,
hese results appear to be sustained. These observations
arrant further investigation with a large, randomized
ulticenter study.
eprint requests and correspondence: Dr. Myung Ho Jeong,
ardiac Catheterization Laboratory, Heart Center of Chonnam
ational University Hospital, 8 Hak-dong, Dong-gu, Gwangju,
01-757, Korea. E-mail: myungho@chollian.net.
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